NuVascular Technologies Inc., a spin-off from BioSurfaces Inc. holds an exclusive license for its nanotechnology platform, developed using $6.6 million in funding from the National Institutes of Health (NIH)t.
“At NuVascular Technologies, our goal is to provide a better treatment for these ailments and help patients live better and longer lives,” Co-Founder Eugene J. Anton said in a statement.
The company is pursuing FDA-approval of its technology.
